Roche launched the Axelios 1 next-generation sequencing (NGS) platform on June 29. The system utilizes Sequencing by Expansion (SBX) technology to compete directly with market leader Illumina.
The Axelios platform delivers same-day whole-genome sequencing results for research laboratories. Roche optimized the system to provide high accuracy, speed, and cost-efficiency.
Initial commercial shipments have commenced to several countries, including the U.S. and Germany. Roche established collaborations with institutions like Broad Clinical Labs to target academic and research facilities.
The company intends to pursue clinical applications for the platform in the future. This launch represents a strategic effort to capture a significant share of the global sequencing market.